Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis

Arthritis and Rheumatology

Volumn 66, Issue 3, 2014, Pages 740-749

  Aggarwal, Rohit ^a   Bandos, Andriy ^a   Reed, Ann M ^b   Ascherman, Dana P ^c   Barohn, Richard J ^d   Feldman, Brian M ^e   Miller, Frederick W ^f   Rider, Lisa G ^f   Harris Love, Michael O ^g   Levesque, Marc C ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

-SIGNAL RECOGNITION PARTICLE ANTIBODY; AUTOANTIBODY; MI 2 ANTIBODY; MJ ANTIBODY; MUSCLE ENZYME; PLACEBO; RITUXIMAB; SYNTHETASE ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1GAMMA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ADULT MYOSITIS; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; EVENT FREE SURVIVAL; FEMALE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; POLYMYOSITIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; POLYMYOSITIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84896277090     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38270     Document Type: Article

References (42)

1. Bohan A, Peter JB. Polymyositis and Dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
2. Bohan A, Peter JB. Polymyositis and Dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
3. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5: 425-30.
4. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiationassociated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 2012;51: 1278-84.
5. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012;51:800-4.
6. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
7. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94: 379-87.
8. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile Dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol 2012;41:50-8.
9. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile Dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010;62:63-72.
10. Sanner H, Kirkhus E, Merckoll E, Tollisen A, Roisland M, Lie BA, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile Dermatomyositis: a case-control study. Arthritis Care Res (Hoboken) 2010;62:1103-11.
11. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
12. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al, the International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003;30:603-17.
13. Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008;58:3593-9.
14. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group. Rituximab in the treatment of refractory adult and juvenile Dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
15. Chiu YE, Co DO. Juvenile Dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use [published erratum appears in Pediatr Dermatol 2011; 28:627]. Pediatr Dermatol 2011;28:357-67.
16. Feldman BM, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001;54: 550-7.
17. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40:1262-73.
18. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney- Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010;62: 465-72.
19. Airio A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and Dermatomyositis patients. Clin Rheumatol 2006; 25:234-9.
20. Danko K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Longterm survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004;83:35-42.
21. Torres C, Belmonte R, Carmona L, Gomez-Reino FJ, Galindo M, Ramos B, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006;39:205-15.
22. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-90, viii.
23. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for Dermatomyositis. N Engl J Med 1993;329:1993-2000.
24. The Muscle Study Group. A randomized, pilot trial of etanercept in Dermatomyositis. Ann Neurol 2011;70:427-36.
25. Bronner IM, van Der Meulen MF, de Visser M, Kalmijn S, van Venrooij WJ, Voskuyl AE, et al. Long-term outcome in polymyositis and Dermatomyositis. Ann Rheum Dis 2006;65:1456-61.
26. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983;26:604-11.
27. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response: antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 1990;85:468-75.
28. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56: 3125-31.
29. Aggarwal R, Oddis CV, Bandos A, Goudeau D, Koontz D, Zenbiao Q, et al. Effect of B cell depletion therapy with rituximab on myositis associated antibody levels in idiopathic inflammatory myopathy [abstract]. Arthritis Rheum 2012;64 Suppl:S325.
30. Wakasugi K, Schimmel P. Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem 1999;274:23155-9.
31. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-51.
32. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196: 781-91.
33. Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen. Ann Rheum Dis 2006;65:242-5.
34. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with Dermatomyositisspecific autoantibodies in adult Japanese patients with Dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147:391-8.
35. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-15.
36. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014;73:227-32.
37. Van Der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-21.
38. Na SJ, Kim SM, Sunwoo IN, Choi YC. Clinical characteristics and outcomes of juvenile and adult Dermatomyositis. J Korean Med Sci 2009;24:715-21.
39. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92:25-41.
40. Marie I, Hatron PY, Levesque H, Hachulla E, Hellot MF, Michon-Pasturel U, et al. Influence of age on characteristics of polymyositis and Dermatomyositis in adults. Medicine (Baltimore) 1999;78:139-47.
41. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and Dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
42. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al, for the IMACS Group. Damage extent and predictors in adult and juvenile Dermatomyositis and polymyositis as determined with the Myositis Damage Index. Arthritis Rheum 2009;60:3425-35. and Skin Diseases